Please Wait a Moment
X

Articles

15Jun

CTS Tampa Implementation date change for Ultrio Elite

15 Jun, 2020 | Return|

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020.  The implementation date has been moved up to July 7th.  Contact your Customer Service Manager if you have any questions!

 

Related

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- August 8th Update

CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...

Read More >

Confirmatory Testing Delay for HIV-1 Western Blot and HIV-2 EIA

Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...

Read More >

National Blood Donor Month

Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...

Read More >

Renewed licenses now available on the website

As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....

Read More >

Reminder-Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

CTS to Implement Licensed Babesia testing

In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols  ...

Read More >